Arrowhead Pharmaceuticals Stock Performance
| ARWR Stock | USD 15.60 0.24 1.56% |
The firm shows a Beta (market volatility) of 1.81, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Arrowhead Pharmaceuticals will likely underperform. At this point, Arrowhead Pharmaceuticals has a negative expected return of -0.53%. Please make sure to confirm Arrowhead Pharmaceuticals' jensen alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if Arrowhead Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Arrowhead Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unsteady performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return 1.56 | Five Day Return 3.52 | Year To Date Return (20.61) | Ten Year Return 106.9 | All Time Return (99.47) |
Last Split Factor 1:10 | Last Split Date 2011-11-17 |
1 | Disposition of 547 shares by Given Douglas B of Arrowhead Pharmaceuticals at 22.04 subject to Rule 16b-3 | 12/17/2024 |
2 | Disposition of 5799 shares by Christopher Anzalone of Arrowhead Pharmaceuticals at 22.12 subject to Rule 16b-3 | 12/18/2024 |
3 | Disposition of 2850 shares by Olukotun Adeoye Y of Arrowhead Pharmaceuticals at 20.0 subject to Rule 16b-3 | 12/27/2024 |
4 | Disposition of 11520 shares by Christopher Anzalone of Arrowhead Pharmaceuticals at 19.05 subject to Rule 16b-3 | 01/02/2025 |
5 | Acquisition by Kenneth Myszkowski of 100000 shares of Arrowhead Pharmaceuticals subject to Rule 16b-3 | 01/03/2025 |
6 | Disposition of 10000 shares by Kenneth Myszkowski of Arrowhead Pharmaceuticals at 19.69 subject to Rule 16b-3 | 01/07/2025 |
7 | Disposition of 959 shares by Olukotun Adeoye Y of Arrowhead Pharmaceuticals at 21.0 subject to Rule 16b-3 | 01/23/2025 |
8 | Insider Selling Arrowhead Pharmaceuticals, Inc. Director Sells 959 Shares of Stock - MarketBeat | 01/27/2025 |
9 | Insider Trading | 02/06/2025 |
10 | Arrowhead Pharmaceuticals Inc Q1 2025 Earnings Call Highlights Strategic Collaborations ... | 02/11/2025 |
11 | ARWR Multiple Catalysts Ahead in 2025 | 02/12/2025 |
12 | Avoro Capital Advisors LLC Increases Stake in Arrowhead Pharmaceuticals Inc | 02/14/2025 |
13 | What is B. Rileys Forecast for ARWR FY2025 Earnings | 02/19/2025 |
14 | Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity | 02/25/2025 |
15 | Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome | 02/28/2025 |
16 | Disposition of 133333 shares by Christopher Anzalone of Arrowhead Pharmaceuticals at 7.75 subject to Rule 16b-3 | 03/03/2025 |
17 | Disposition of 133333 shares by Christopher Anzalone of Arrowhead Pharmaceuticals at 17.02 subject to Rule 16b-3 | 03/04/2025 |
18 | Edgestream Partners L.P. Makes New 2.26 Million Investment in Arrowhead Pharmaceuticals, Inc. | 03/10/2025 |
| Begin Period Cash Flow | 110.9 M |
Arrowhead |
Arrowhead Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 2,227 in Arrowhead Pharmaceuticals on December 17, 2024 and sell it today you would lose (667.00) from holding Arrowhead Pharmaceuticals or give up 29.95% of portfolio value over 90 days. Arrowhead Pharmaceuticals is currently does not generate positive expected returns and assumes 3.6127% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Arrowhead, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Arrowhead Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arrowhead Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Arrowhead Pharmaceuticals, and traders can use it to determine the average amount a Arrowhead Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1458
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ARWR |
Estimated Market Risk
| 3.61 actual daily | 32 68% of assets are more volatile |
Expected Return
| -0.53 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Arrowhead Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Arrowhead Pharmaceuticals by adding Arrowhead Pharmaceuticals to a well-diversified portfolio.
Arrowhead Pharmaceuticals Fundamentals Growth
Arrowhead Stock prices reflect investors' perceptions of the future prospects and financial health of Arrowhead Pharmaceuticals, and Arrowhead Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Arrowhead Stock performance.
| Return On Equity | -5.65 | ||||
| Return On Asset | -0.48 | ||||
| Operating Margin | (64.56) % | ||||
| Current Valuation | 2.08 B | ||||
| Shares Outstanding | 137.32 M | ||||
| Price To Earning | 482.39 X | ||||
| Price To Book | 40.11 X | ||||
| Price To Sales | 843.68 X | ||||
| Revenue | 3.55 M | ||||
| Gross Profit | 2.5 M | ||||
| EBITDA | (561.51 M) | ||||
| Net Income | (609.69 M) | ||||
| Cash And Equivalents | 416.5 M | ||||
| Cash Per Share | 3.93 X | ||||
| Total Debt | 510.55 M | ||||
| Debt To Equity | 0.17 % | ||||
| Current Ratio | 3.37 X | ||||
| Book Value Per Share | 0.42 X | ||||
| Cash Flow From Operations | (462.85 M) | ||||
| Earnings Per Share | (5.15) X | ||||
| Market Capitalization | 2.11 B | ||||
| Total Asset | 1.14 B | ||||
| Retained Earnings | (1.63 B) | ||||
| Working Capital | 592.3 M | ||||
| Current Asset | 90.5 M | ||||
| Current Liabilities | 25.64 M | ||||
About Arrowhead Pharmaceuticals Performance
Assessing Arrowhead Pharmaceuticals' fundamental ratios provides investors with valuable insights into Arrowhead Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Arrowhead Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (681.34) | (647.27) | |
| Return On Tangible Assets | (0.48) | (0.50) | |
| Return On Capital Employed | (0.67) | (0.70) | |
| Return On Assets | (0.47) | (0.50) | |
| Return On Equity | (3.72) | (3.53) |
Things to note about Arrowhead Pharmaceuticals performance evaluation
Checking the ongoing alerts about Arrowhead Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Arrowhead Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Arrowhead Pharmaceuticals generated a negative expected return over the last 90 days | |
| Arrowhead Pharmaceuticals has high historical volatility and very poor performance | |
| Arrowhead Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 3.55 M. Net Loss for the year was (609.69 M) with profit before overhead, payroll, taxes, and interest of 2.5 M. | |
| Arrowhead Pharmaceuticals currently holds about 416.5 M in cash with (462.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.93. | |
| Arrowhead Pharmaceuticals has a very weak financial position based on the latest SEC disclosures | |
| Roughly 75.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Edgestream Partners L.P. Makes New 2.26 Million Investment in Arrowhead Pharmaceuticals, Inc. |
- Analyzing Arrowhead Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Arrowhead Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Arrowhead Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Arrowhead Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Arrowhead Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Arrowhead Pharmaceuticals' stock. These opinions can provide insight into Arrowhead Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.